Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
Route: INTRAMUSCULAR; Dosage form: INJECTION; Potency: 1 %w/v
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 5/100 · limited confidence.
Catalog
Co-occurrence
Ingredients that frequently appear alongside CROSCARMELLOSE SODIUM in the catalog.
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
The published evidence profile currently shaping this ingredient record.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
FDA
Route: INTRAMUSCULAR; Dosage form: INJECTION; Potency: 1 %w/v
US
FDA
Route: ORAL; Dosage form: CAPSULE; Maximum daily exposure: 257 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, COATED PELLETS; Maximum daily exposure: 198 mg
Doctor's Best, High Absorption Magnesium
Doctor's Best
US
FDA
Route: ORAL; Dosage form: CAPSULE, DELAYED RELEASE; Maximum daily exposure: 72 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, DELAYED RELEASE PELLETS; Maximum daily exposure: 127 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, EXTENDED RELEASE; Maximum daily exposure: 53 mg
US
FDA
Route: ORAL; Dosage form: GRANULE; Maximum daily exposure: 150 mg
US
FDA
Route: ORAL; Dosage form: GRANULE, FOR SUSPENSION; Maximum daily exposure: 282 mg
US
FDA
Route: ORAL; Dosage form: PELLET; Maximum daily exposure: 162 mg
US
FDA
Route: ORAL; Dosage form: POWDER, FOR SUSPENSION; Potency: 11.25 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 150 mg
US
FDA
Route: ORAL; Dosage form: TABLET; Maximum daily exposure: 736 mg
US
FDA
Route: ORAL; Dosage form: TABLET, CHEWABLE; Maximum daily exposure: 216 mg
US
FDA
Route: ORAL; Dosage form: TABLET, COATED; Maximum daily exposure: 224 mg
US
FDA
Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Maximum daily exposure: 280 mg
US
FDA
Route: ORAL; Dosage form: TABLET, DELAYED RELEASE PARTICLES; Maximum daily exposure: 64 mg
US
FDA
Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Maximum daily exposure: 392 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FILM COATED; Maximum daily exposure: 330 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FOR SUSPENSION; Maximum daily exposure: 1875 mg
US
FDA
Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING; Maximum daily exposure: 184 mg
US
FDA
Route: ORAL; Dosage form: TROCHE; Maximum daily exposure: 50 mg
US
FDA
Route: SUBLINGUAL; Dosage form: TABLET; Maximum daily exposure: 10 mg
US
FDA
openFDA substance registry classifies this ingredient as polymer.